 Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsedrefractory B-cell Lymphoma. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsedrefractory B-cell Lymphoma are expected by the end of 2022. 